Francia - francese - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - lisinopril anhydre 20 mg sous forme de : lisinopril dihydraté; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > lisinopril anhydre 20 mg sous forme de : lisinopril dihydraté > hydrochlorothiazide 12,5 mg - inhibiteur de l'enzyme de conversion (iec) et diurétiques - classe pharmacothérapeutique : inhibiteur de l'enzyme de conversion (iec) et diurétiques - code atc : c09ba03.ce médicament est indiqué dans le traitement de : l'hypertension artérielle, en cas de contrôle insuffisant sous un seul médicament (inhibiteur de l'enzyme de conversion).

Francia - francese - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

sandoz - lisinopril anhydre 20 mg sous forme de : lisinopril dihydraté; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > lisinopril anhydre 20 mg sous forme de : lisinopril dihydraté > hydrochlorothiazide 12,5 mg - inhibiteur de l'enzyme de conversion (iec) et diuretiques - code atc : c09ba03. - classe pharmacothérapeutique : inhibiteur de l'enzyme de conversion (iec) et diuretiques - code atc : c09ba03.ce médicament est indiqué dans le traitement de : l’hypertension artérielle, en cas de contrôle insuffisant sous un seul médicament (inhibiteur de l’enzyme de conversion).

Stati Uniti - inglese - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - lisinopril 20 mg - lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed-dose combinations are not indicated for initial therapy (see dosage and administration ). in using lisinopril and hydrochlorothiazide tablets, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (see warnings .) in considering the use of lisinopril and hydrochlorothiazide tablets, it should be noted that ace inhibitors have been associated with a higher rate of angioedema in black than in non-black patients.(see warnings ,lisinopril . ) lisinopril and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme in

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 21.78 mg - tablet - excipient ingredients: croscarmellose sodium; mannitol; maize starch; magnesium stearate; iron oxide red; calcium hydrogen phosphate dihydrate - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 10.89 mg - tablet - excipient ingredients: mannitol; iron oxide red; maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; croscarmellose sodium - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 5.44 mg - tablet - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; croscarmellose sodium; iron oxide red - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Portogallo - portoghese - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lisinopril + hidroclorotiazida - comprimido - 20 mg + 12.5 mg - lisinopril, di-hidratado 21.78 mg ; hidroclorotiazida 12.5 mg - lisinopril and diuretics - genérico - duração do tratamento: longa duração

Portogallo - portoghese - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lisinopril + hidroclorotiazida - comprimido - 20 mg + 12.5 mg - lisinopril, di-hidratado 21.78 mg ; hidroclorotiazida 12.5 mg - lisinopril and diuretics - genérico - duração do tratamento: longa duração

Portogallo - portoghese - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lisinopril + hidroclorotiazida - comprimido - 20 mg + 12.5 mg - lisinopril, di-hidratado 21.78 mg ; hidroclorotiazida 12.5 mg - lisinopril and diuretics - genérico - duração do tratamento: longa duração

Portogallo - portoghese - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lisinopril + hidroclorotiazida - comprimido - 20 mg + 12.5 mg - lisinopril, di-hidratado 21.78 mg ; hidroclorotiazida 12.5 mg - lisinopril and diuretics - genérico - duração do tratamento: longa duração